# US Patent 10,705,070: Claim Scope, Patent Landscape, Exclusivity and Generic-Entry Risk for Albumin-Bound Rapamycin

US Patent 10,705,070 protects quality-control, batch-validation and batch-release procedures for albumin-coated rapamycin nanoparticles. It does not broadly claim rapamycin, albumin-bound rapamycin nanoparticles, or a therapeutic method of administering the product. The core inventive concept is the use of defined albumin aggregation, particle, coating, solubility, crystallinity, filtration-recovery and composition-ratio parameters to determine whether a pharmaceutical batch is suitable for human use.[1]

The patent is most relevant to products based on nab-sirolimus or another albumin-bound rapamycin formulation. Its commercial significance depends on whether a competing developer uses the claimed analytical thresholds as part of manufacturing validation, commercial release, or batch disposition.

What does US Patent 10,705,070 cover?

The patent covers three related categories:

Claim category	Claims	Protected subject matter
Suitability-assessment methods	1-27, 30-31	Testing a rapamycin nanoparticle composition against specified quality attributes
Commercial-batch validation	28	Sampling and validating a commercial batch using the claimed assessment method
Validated batch and batch release	29, 32-33	A validated commercial batch, release of a batch after testing, and processing a sample for validation

The composition tested by the claims has two required portions:

Nanoparticles containing rapamycin and coated with albumin.
A non-nanoparticle portion containing albumin and rapamycin.

This two-phase structure is important. A formulation consisting only of purified albumin-coated rapamycin nanoparticles may fall outside the literal language if it lacks the claimed non-nanoparticle albumin-and-rapamycin portion.

The claims also require separation of the nanoparticles from the non-nanoparticle portion before at least the principal albumin measurements are performed. A test applied to the bulk formulation without separating those fractions may not satisfy the express steps of claims 1 and 2.

What are the independent claims in US 10,705,070?

Claims 1 and 2 are the principal analytical method claims.

Claim 1 requires measuring the percentage of albumin polymers in the nanoparticle coating. A polymer content of approximately 15% to 40% indicates suitability for human medical use.

Claim 2 requires measuring the percentage of albumin monomers in the nanoparticle coating. A monomer content of approximately 40% to 60% indicates suitability.

Claim 28 covers validation of a commercial batch by obtaining a sample and applying claim 2.

Claim 29 covers a commercial batch that has been validated under claim 2.

Claim 32 covers release of a commercial batch after the suitability assessment.

Claim 33 covers processing a commercial-batch sample and assessing its suitability under claim 2.

Claims 29, 32 and 33 extend the patent beyond laboratory characterization. They connect the analytical method to commercial manufacturing operations and release decisions.

What analytical specifications are protected?

The dependent claims create a detailed quality-control fingerprint for the nanoparticle formulation.

Parameter	Claimed range or result	Claims
Albumin polymers in nanoparticle coating	About 15% to 40% of total coating albumin	1
Albumin monomers in nanoparticle coating	About 40% to 60% of total coating albumin	2, 3
Albumin monomers below threshold	Less than about 51%	30
Albumin in coating relative to nanoparticle weight	About 15% to 30%	4
Albumin-to-rapamycin ratio in nanoparticles	About 1:2 to 1:6	5
Coating thickness	About 5 nm to 7 nm by cryogenic TEM	6
Solubility in 5% human albumin	About 50 µg/mL to 100 µg/mL by DLS	7, 10
Rapamycin physical state	Non-crystalline	8
Rapamycin recovery after 0.2 µm filtration	At least about 80%	9
Albumin dimers in coating	About 15% to 30%	11
Albumin oligomers in coating	About 7% to 15%	12
Albumin size distribution	Determined by size-exclusion chromatography	13, 14, 23
Nanoparticle size	Less than about 200 nm	27
Particle-size testing	Dynamic light scattering	16
Rapamycin quantitation	Reversed-phase HPLC	20, 21
Nanoparticle distribution	Polydispersity index or span	17, 18
Surface characterization	Surface potential	19
Total albumin-to-rapamycin ratio	About 3:1 to 7.9:1 or 10:1 to 17:1	25
Albumin source	Human albumin	26
Polymer plus oligomer to monomer ratio	More than about 65%	31

The claims do not require every listed parameter in every case. Most parameters are optional limitations added through dependent claims. A competitor could therefore avoid literal infringement of a narrow dependent claim while still implicating claim 1, claim 2, claim 28, claim 32 or claim 33.

How strong are the core claims?

Claim 1: polymer-based suitability testing

Claim 1 is relatively narrow because it requires:

rapamycin-containing albumin-coated nanoparticles;
a non-nanoparticle albumin-and-rapamycin fraction;
separation of the two portions;
measurement of polymeric albumin in the separated nanoparticle coating; and
a polymer range of about 15% to 40% as the suitability indicator.

The claim may be difficult to apply to a formulation that uses a different stabilizing protein, has no measurable non-nanoparticle fraction, or assesses polymer content in the bulk formulation rather than the separated coating.

Claim 2: monomer-based suitability testing

Claim 2 is the central independent claim because many dependent claims refer back to it. It covers a monomer range of about 40% to 60%. Claim 30 narrows the monomer result to less than about 51%.

The overlap between "about 40% to about 60%" and "less than about 51%" creates a practical release window centered around 40% to 50.9%. A batch can satisfy both limitations if the measured monomer percentage is within the overlapping range.

Claims 28, 32 and 33: manufacturing and release exposure

These claims are commercially important because they target activities performed by a sponsor, contract manufacturer or finished-dose manufacturer.

A company that uses the claimed assay only during research may face a different risk profile from a company that:

samples each commercial batch;
applies the monomer threshold to determine suitability;
validates a batch under the patent;
releases the batch based on the claimed method; or
documents the claimed assessment in its manufacturing records.

The claims do not expressly require a particular manufacturing process. They focus on testing and decision-making.

Claim 29: validated commercial batch

Claim 29 is a product-by-process-style claim directed to a commercial batch validated by the claim 2 assessment. Its enforceability may depend on how the court interprets "commercial batch" and "validated by assessment." The claim does not specify a unique particle size, rapamycin loading, coating thickness or therapeutic indication on its face.

What does the patent not cover?

The patent does not expressly claim:

rapamycin or sirolimus as a chemical compound;
oral sirolimus tablets or solutions;
a therapeutic method for treating cancer, lymphangioleiomyomatosis or transplant rejection;
albumin-bound paclitaxel;
every albumin-coated rapamycin nanoparticle;
a specific nanoparticle manufacturing process;
a specific route of administration;
a specific dosage regimen; or
a broad composition claim independent of validation status.

That distinction limits the patent’s direct blocking effect. A competing product may avoid infringement by using a formulation that lacks the claimed two-fraction structure or by using a different release specification and a different testing sequence.

When does US Patent 10,705,070 lose exclusivity?

The patent issued on July 7, 2020.[1] Patent term is generally 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers and applicable continuity rules.[2]

The claims supplied do not establish the earliest effective filing date, patent-term adjustment, terminal disclaimer status or any patent-term extension. An exact expiration date therefore cannot be derived from the claim text alone.

On an ordinary 20-year-term basis, the patent is likely to remain relevant into the 2030s if its priority chain began in the mid-2010s. A definitive expiration calculation must be based on the USPTO continuity and patent-term records, not the grant date.

This patent should be analyzed separately from:

regulatory exclusivity;
any patents claiming the nanoparticle composition itself;
patents covering manufacturing or scale-up;
patents directed to a particular oncology indication; and
patents covering formulation stability or administration.

Expiration of US 10,705,070 would not necessarily create freedom to market the underlying albumin-bound rapamycin product if other patents remain enforceable.

What is the Orange Book status of the patent?

US 10,705,070 is not, based on the claim scope supplied, an obvious Orange Book patent for an approved drug product. Its claims are directed principally to analytical assessment and commercial-batch validation rather than to an approved drug’s composition, formulation, method of use or approved method of manufacture.

FDA Orange Book listing generally concerns patents submitted for approved drug products under the Hatch-Waxman framework.[3] The relevance of this patent to an ANDA Paragraph IV certification would depend on:

whether an FDA-approved reference product contains the claimed albumin-bound rapamycin formulation;
whether the patent is submitted and accepted for listing against that product;
whether the listed claims are properly listable; and
whether the ANDA product or its manufacturing and release procedures practice the claims.

Rapamune is an FDA-approved sirolimus product, but it is not an albumin-coated rapamycin nanoparticle product.[4] The existence of FDA approval for Rapamune does not by itself make US 10,705,070 an Orange Book barrier to generic oral sirolimus.

As of the information reflected in the claim set, the more relevant pathway for an albumin-bound rapamycin product would likely be a new drug application, a 505(b)(2) application or another product-specific regulatory route, rather than a conventional ANDA relying on Rapamune.

Are there Paragraph IV challenges to US 10,705,070?

No Paragraph IV challenge can be inferred from the patent claims. Paragraph IV litigation requires an ANDA applicant to certify that a listed patent is invalid, unenforceable or not infringed.[5]

The practical risk is limited unless all of the following conditions exist:

an approved albumin-bound rapamycin reference product;
an Orange Book listing for this patent;
an ANDA applicant seeking approval of a therapeutically equivalent product; and
a certification directed to the listed patent.

If the product is not approved as an ANDA-reference product, a direct Paragraph IV pathway is less likely. Patent litigation could still arise through a declaratory-judgment action, a licensing dispute, a commercial manufacturing dispute or an infringement action based on batch testing and release activities.

Which companies are most exposed?

The principal exposure is concentrated in companies developing albumin-bound rapamycin or nab-sirolimus products, including sponsors, licensees and contract manufacturers using the claimed specifications.

Innovator and licensee exposure

An innovator may own or license separate patents covering:

rapamycin nanoparticle composition;
albumin coating architecture;
nanoparticle preparation;
cancer treatment methods;
formulation stability;
sterile filtration;
lyophilization or reconstitution; and
commercial manufacturing.

US 10,705,070 can operate as a quality-control patent within that broader estate. It is most valuable where the sponsor’s release specification mirrors the claimed albumin monomer or polymer ranges.

Contract manufacturing exposure

A contract manufacturer may practice the claims even where it does not own the patent. Risk increases if the manufacturer:

performs the separation step;
conducts SEC, DLS, HPLC, cryo-TEM or filtration-recovery testing;
determines batch suitability; or
releases the batch for commercial distribution.

Indemnity and manufacturing-services agreements should allocate responsibility for patent clearance, validation assays and batch release decisions.

Generic and follow-on developers

A follow-on developer can reduce risk by changing one or more claim elements:

eliminate or minimize the claimed non-nanoparticle fraction;
use a different protein coating;
use a different albumin aggregation profile;
define release criteria outside the claimed ranges;
use a different particle-production process; or
conduct development testing without using the claimed suitability thresholds.

Avoiding the exact assay may not be enough if the commercial batch is independently found to satisfy the claimed product-by-process limitation of claim 29.

What litigation and licensing issues matter?

The claims create several likely dispute points.

Infringement

A patent owner would need to establish each required claim element. For claims 1 and 2, the separation step and the measured albumin species are central. A broad allegation that a product contains albumin-bound rapamycin would not establish infringement.

Claim construction

Potential disputes include the meaning of:

"about" in the numerical ranges;
"albumin polymers";
"albumin oligomers";
"coating";
"non-nanoparticle portion";
"commercial batch";
"validated"; and
"indicative of suitability."

The analytical method used to distinguish monomers, dimers, oligomers and polymers can materially affect infringement. SEC conditions, calibration standards, sample preparation and fraction assignment may become critical evidence.

Enablement and written description

The patent’s validity may be tested against whether the specification supports the full breadth of the numerical ranges and analytical methods. A challenger could examine whether the disclosure supports all rapamycin-albumin nanoparticle compositions within the claimed ranges or only a particular formulation.

Obviousness

Potential prior art includes:

albumin-bound nanoparticle drug-delivery systems;
sirolimus or rapamycin nanoparticle formulations;
SEC analysis of albumin aggregation;
DLS characterization;
cryogenic electron microscopy;
filtration-recovery testing; and
pharmaceutical batch-release methods.

The strongest validity question is whether the claimed thresholds were an expected result of known formulation optimization or an experimentally identified quality attribute linked to clinical suitability.

Licensing

A license should address the right to perform:

process validation;
analytical testing;
commercial batch release;
contract manufacturing;
regulatory submissions;
post-approval changes; and
testing by affiliates and third-party laboratories.

A license limited to research use may not cover commercial release testing under claims 28, 32 or 33.

How does this patent compare with composition and method-of-use patents?

Patent type	Typical scope	Relevance of US 10,705,070
Composition patent	Covers the nanoparticle or drug-protein structure	Separate and potentially broader product barrier
Manufacturing patent	Covers preparation, mixing, homogenization, solvent removal or sterilization	Separate process risk
Formulation patent	Covers reconstitution, excipients, concentration or stability	Separate finished-product risk
Method-of-use patent	Covers treatment of a disease or patient population	Separate clinical-use barrier
Quality-control patent	Covers analytical attributes and batch decisions	Directly relevant to US 10,705,070
Regulatory patent	Covers approved use or delivery system tied to regulatory filing	Depends on listing and product status

US 10,705,070 is narrower than a composition patent in product coverage but can be difficult to design around if the sponsor’s validated commercial process uses the claimed thresholds.

What generic launch scenarios exist?

Scenario 1: No approved albumin-bound rapamycin reference product

Paragraph IV risk is limited. The principal issues are freedom to operate, licensing and potential infringement during commercial manufacturing or product release.

Scenario 2: Follow-on product uses a different quality system

Risk is lower if the developer does not separate the same fractions or use the claimed monomer/polymer thresholds as suitability criteria. Other composition or manufacturing patents may still block launch.

Scenario 3: Follow-on product meets the claimed attributes but uses different terminology

Risk remains material. Infringement may turn on the underlying measurements rather than the wording used in the batch record. A company may not avoid the claims merely by labeling the same fractions as "high-molecular-weight albumin" or "aggregated albumin."

Scenario 4: Product is manufactured outside the United States

Foreign manufacturing does not automatically eliminate U.S. exposure. Importation, U.S. commercial release, U.S. testing and U.S. distribution can create separate infringement theories under the Patent Act.[2] Geographic analysis must cover manufacturing, testing laboratories, batch release and importation locations.

Key Takeaways

US 10,705,070 is a quality-control and batch-release patent for albumin-coated rapamycin nanoparticles.
Claims 1 and 2 are the core independent claims, centered on albumin polymer and monomer percentages in the separated nanoparticle coating.
Claims 28, 29, 32 and 33 extend coverage into commercial-batch validation and release.
The patent does not broadly claim rapamycin, sirolimus, all albumin nanoparticles or a therapeutic method.
The required non-nanoparticle albumin-and-rapamycin portion is a significant claim limitation.
SEC, DLS, cryo-TEM, X-ray diffraction, polarized microscopy, HPLC and filtration-recovery testing are expressly incorporated into the dependent-claim architecture.
Exact patent expiration requires the USPTO continuity and patent-term records. The grant date alone does not establish expiration.
Paragraph IV risk depends on an approved and Orange Book-listed albumin-bound rapamycin reference product. Rapamune approval does not, by itself, create that pathway.
Commercial manufacturers and sponsors face the greatest exposure when the patented thresholds are embedded in batch-release specifications.
The patent should be evaluated together with composition, manufacturing, formulation and method-of-use patents covering the underlying nab-sirolimus product.

FAQs

Does US 10,705,070 claim nab-sirolimus itself?

No. The patent claims methods for assessing and validating an albumin-coated rapamycin nanoparticle composition. It does not broadly claim the active ingredient or every nab-sirolimus composition.

Can a company avoid the patent by using dynamic light scattering instead of SEC?

Not necessarily. DLS is required only in certain dependent claims. Claims 1 and 2 focus on separating the nanoparticles and measuring albumin polymers or monomers in the coating. Avoiding DLS may avoid claims 7, 10 or 16, but it does not necessarily avoid the independent claims.

Does claim 29 cover every batch of albumin-bound rapamycin?

No. Claim 29 requires a commercial batch containing the specified nanoparticle and non-nanoparticle portions and requires validation by the claim 2 assessment. A batch outside those limitations may not fall within the claim.

Is the patent relevant to generic Rapamune tablets?

Generally no. Rapamune is an approved sirolimus product, while US 10,705,070 concerns albumin-coated rapamycin nanoparticles and their batch-validation characteristics.[4]

What evidence would be important in an infringement dispute?

The key evidence would include batch records, release specifications, analytical protocols, SEC chromatograms, nanoparticle-separation procedures, DLS data, HPLC results, filtration-recovery results and documents identifying the criteria used to determine suitability for human use.

References

United States Patent and Trademark Office. (2020). U.S. Patent No. 10,705,070, methods of assessing pharmaceutical compositions comprising nanoparticles.
United States Code. (2023). 35 U.S.C. §§ 154, 271.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2023). Rapamune (sirolimus) prescribing information. Pfizer Laboratories.
United States Code. (2023). 21 U.S.C. § 355(j)(2)(A)(vii)(IV).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Aadi	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes	10,705,070	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Summary for Patent: 10,705,070